Dapsone therapy causing sulfone syndrome and lethal hepatic failure in an HIV-infected patient.
A 34-year-old woman with HIV infection and no other opportunistic infections presented a classic sulfone syndrome, manifested by fever, rash, hemolytic anemia, and fulminant hepatitis due to dapsone hypersensitive reaction, with a fatal outcome. We believe this is the first reported fatal complication of dapsone in an HIV-infected patient. We to bring attention to this potentially fatal drug complication, which may become more common with widespread use of dapsone in HIV-infected patients. The package insert for dapsone recommends laboratory surveillance (hematologic and liver-related tests) during the first 4 to 6 weeks of therapy, and every 3 to 4 months thereafter. Our case report suggests that closer follow-up of patients receiving dapsone might be indicated.
Department of Medicine, Emory University School of Medicine, Atlanta, Ga.
P
P
Chalasani
H
H
Baffoe-Bonnie
R L
RL
Jurado
D017088:AIDS-Related Opportunistic Infections / Q000517:prevention & control*; D000328:Adult; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology; D003622:Dapsone / Q000009:adverse effects* / Q000627:therapeutic use; D004342:Drug Hypersensitivity / Q000209:etiology*; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D017114:Liver Failure, Acute / Q000139:chemically induced*; D011020:Pneumonia, Pneumocystis / Q000517:prevention & control*; D013577:Syndrome
D003622:Dapsone